Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma.

Journal Article (Journal Article;Review)

Adjuvant chemotherapy for osteosarcoma and Ewing sarcoma consists of conventional cytotoxic regimens that have changed little over the past decades. There is an urgent need for agents that are more effective and have less long-term toxicity. Receptor tyrosine kinases regulate cell growth and proliferation of these tumors, and small-molecule inhibitors for many of these kinases are now available. In this article, we review published phase II trials for patients with recurrent disease and highlight the pathways targeted by available agents, as well as the toxicity and efficacy results seen to date. We also discuss the difficulties in identifying biomarkers to facilitate rational patient selection, as well as published and proposed strategies for how these inhibitors can be combined with conventional chemotherapy or other targeted agents. It is hoped future trials can capitalize on this growing experience to optimize the use of this exciting class of agents.

Full Text

Duke Authors

Cited Authors

  • Just, MA; Van Mater, D; Wagner, LM

Published Date

  • August 2021

Published In

Volume / Issue

  • 68 / 8

Start / End Page

  • e29084 -

PubMed ID

  • 33894051

Pubmed Central ID

  • PMC8238849

Electronic International Standard Serial Number (EISSN)

  • 1545-5017

Digital Object Identifier (DOI)

  • 10.1002/pbc.29084


  • eng

Conference Location

  • United States